$CL

Colgate-Palmolive Lifts FY26 Adj. Earnings View, Despite Weak Q2 Profit; Stock Down

Colgate-Palmolive reported Q2 net earnings of $693 million, down from $743 million a year earlier, with EPS falling to $0.86 from $0.91. Net sales rose to $5.361 billion. The company confirmed FY2026 outlook and raised Base Business EPS growth to mid-single-digit from low- to mid-single-digit, and expects gross margin roughly flat. Shares were down about 2.78% premarket.

Original reporting
Published Jul 31, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CL
Bullish
medium confidence
Mentioned
$CL
Relevance
7/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$CLBullishMed
01

Why it matters

Traders can reprice CL’s FY26 earnings trajectory based on the specific guidance revisions, especially the shift to mid-single-digit Base Business EPS growth and gross margin roughly flat.

02

Market read

A guidance upgrade on earnings quality (Base Business EPS) and margin outlook is a fresh catalyst that can drive pre-market positioning even with a reported Q2 profit decline.

03

What to watch

The guidance still expects only modest net sales growth (2% to 6%) and includes headwinds from the private label pet food exit, so upside may be limited if volume trends weaken again.

Relevance 7/10Novelty 6/10Timing: pre-market today, after Q2 results and FY26 guidance update

Background

Colgate-Palmolive reported weaker Q2 net earnings but higher net sales, then confirmed FY26 outlook while raising Base Business EPS and gross profit margin expectations.

Company-level read

Ticker impact

$CLBullishMedium confidence
Context

Colgate-Palmolive lifted FY26 Base Business EPS and gross margin outlook, despite Q2 profit weakness and a stock drop of about 2.78% premarket.

Expected impact

Likely near-term support for CL versus peers, with follow-through depending on whether investors focus on Base Business vs reported EPS.

Evidence & confidence

The article provides a concrete change in FY26 outlook (Base Business EPS mid-single-digit vs prior low-to-mid-single-digit, and gross margin roughly flat vs prior drop) plus the reported Q2 earnings miss, giving traders a clear decision point for positioning.

Market effects

Signals resilience in consumer staples earnings quality via premium, science-led innovation and margin stabilization, relevant for discretionary pricing power read-through.

Highlights regional divergence, with North America down 3% and Latin America up 13.7%, which can influence regional consumer staples sentiment.

Reinforces global portfolio strength narrative and FX contribution (low-single-digit positive) for multinational consumer products investors.

Counterpoint

Investors may discount Base Business improvements if reported EPS growth remains only double-digit on a reported basis while near-term demand volatility persists.

Key entities

  • Colgate-Palmolive Co.

    Consumer products company confirming FY26 outlook while lifting Base Business EPS and gross profit margin guidance after Q2 results.

  • Noel Wallace

    CEO who reiterated strategy execution and confidence in compounded EPS growth despite volatile market conditions.

Related articles

$CLMed

Colgate-Palmolive Reaffirms Sales Forecast On Weak Demand

Colgate-Palmolive reaffirmed its annual net sales forecast despite a quarterly rise, citing weak North America demand. In the quarter ended June 30, net sales rose 4.9% to $5.36 billion and adjusted EPS was 99 cents. North America organic sales fell 3%, with volumes down 3.9%. The company expects 2026 adjusted earnings growth in mid-single digits and warned tariffs could offset refunds.

$CLMed

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported Q2 2026 Base Business diluted EPS up 8% to $0.99 from $0.92, driven by 140 bps gross-margin expansion to 61.5% and higher organic sales. Reported diluted EPS fell 5% to $0.86 due to $129m pretax charges tied to its Strategic Growth and Productivity Program. Net sales rose 4.9% to $5.36b. Full-year organic outlook 1% to 4%; Base Business EPS expected mid-single-digit growth.

$CLMed

Colgate-Palmolive Q2 Earnings Call Highlights

Colgate-Palmolive (NYSE:CL) CFO Stan Sutula said Q2 material costs were slightly below expectations due to higher raw-material costs offset by tariff refunds, with no meaningful additional refunds expected. Management now expects full-year gross margin roughly flat, and warned second-half raw-material and tariff costs will be higher. It plans elevated ad spending and North America share recovery; Hill’s organic sales rose 4% excluding discontinued private-label.

$CLHighAI 9/10

Colgate-Palmolive Q2 2026 slides: strong results fuel raised guidance

Colgate-Palmolive (NYSE:CL) reported Q2 2026 results on July 31. Net sales rose 4.9% to $5.36B and organic sales grew 2.4%. Base EPS increased 8% and free cash flow rose 18% YoY to $1.5B YTD. The company raised 2026 guidance, including flat gross margin outlook and higher EPS growth, and projected $350M to $550M pre-tax charges for its 2030 program.

$CLMed

Colgate-Palmolive reaffirms annual sales forecast on weak North America demand

Amazon shares rally as cloud growth surges and spending outlook climbs July 31 (Reuters) - Colgate-Palmolive on Friday reaffirmed its annual sales forecast even after posting a quarterly rise as the toothpaste maker continues to grapple with muted demand in North America, sending its shares down 2.5%. Higher food and fuel prices tied to the Middle East conflict have hit lower-income shoppers hard, making it harder for U.S.